On the public citation graph
Glimepiride Pharmacokinetics in Obese Versus Non-Obese Diabetic Patients
0 signed · 52 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/0168-8227(95)01072-lopenalex-snapshot
Clinical profile of glimepiride
inferredcites →https://doi.org/10.1016/s0378-4347(00)82531-1openalex-snapshot
Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization
inferredcites →https://doi.org/10.1055/s-2007-979829openalex-snapshot
An Overview of the Safety and Tolerance of Glimepiride
inferredcites →https://doi.org/10.1055/s-2007-979831openalex-snapshot
Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative Study
inferredcites →https://doi.org/10.1055/s-2007-979833openalex-snapshot
Pharmacokinetic Basis for the Safety of Glimepiride in Risk Groups of NIDDM Patients
inferredcites →https://doi.org/10.1056/nejm198908103210601openalex-snapshot
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
inferredcites →https://doi.org/10.1111/j.1749-6632.1957.tb54569.xopenalex-snapshot
THE HYPOGLYCEMIC SULFONAMIDES: HISTORY AND DEVELOPMENT OF THE PROBLEM FROM 1942 TO 1955
inferredcites →https://doi.org/10.1177/106002809703100601openalex-snapshot
Short-Term Comparison of Once- versus Twice-Daily Administration of Glimepiride in Patients with Non-Insulin-Dependent Diabetes Mellitus
inferredcites →https://doi.org/10.1345/aph.17360openalex-snapshot
Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.2165/00003495-199958001-00004openalex-snapshot
Pathogenesis of Insulin Resistance in Type 2 Diabetes
inferredcites →https://doi.org/10.2337/diacare.19.11.1194openalex-snapshot
Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
inferredcites →https://doi.org/10.2337/diacare.20.10.1512openalex-snapshot
Impact of Dosage Frequency on Patient Compliance
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4765193openalex-extracted
Synergistic Effects of Sulfonylureas with Chemotherapeutics: In Vitro Screening Reveals Enhanced Cytotoxicity of Doxorubicin in Combination with Sulfonylureas
inferred← citeshttps://doi.org/10.1002/bmc.70478openalex-snapshot
Three Decades of Glimepiride Analysis: A Review of Analytical and Bioanalytical Methods
inferred← citeshttps://doi.org/10.1002/jps.23085openalex-snapshot
Type 2 Diabetes in Pediatrics and Adults: Thoughts from a Clinical Pharmacology Perspective
inferred← citeshttps://doi.org/10.1002/msj.20072openalex-snapshot
Impact of obesity on hospitalized patients
inferred← citeshttps://doi.org/10.1007/s12272-011-1210-0openalex-snapshot
Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometry
inferred← citeshttps://doi.org/10.1007/s40262-014-0192-8openalex-snapshot
Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model
inferred← citeshttps://doi.org/10.1007/s40262-022-01194-3openalex-snapshot
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
inferred← citeshttps://doi.org/10.1016/j.apme.2013.05.002openalex-snapshot
Safety and Efficacy of Sulfonylurea Drugs in Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115281openalex-snapshot
Pharmacokinetics of obese adults: Not only an increase in weight
inferred← citeshttps://doi.org/10.1016/j.bmcl.2009.01.082openalex-snapshot
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents
inferred← citeshttps://doi.org/10.1016/j.cjca.2014.10.025openalex-snapshot
The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control
inferred← citeshttps://doi.org/10.1016/j.clinthera.2009.11.001openalex-snapshot
Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: A single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers
inferred← citeshttps://doi.org/10.1016/j.ejmech.2026.119009openalex-snapshot
Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956–2025)
inferred← citeshttps://doi.org/10.1016/j.jddst.2024.105808openalex-snapshot
Cubosomes: An emerging nanodrug delivery platform for anti-diabetic medications
inferred← citeshttps://doi.org/10.1016/j.jsps.2017.01.002openalex-snapshot
A rapid hydrophilic interaction liquid chromatographic determination of glimepiride in pharmaceutical formulations
inferred← citeshttps://doi.org/10.1016/s0140-6736(11)61879-5openalex-snapshot
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.9b00897openalex-snapshot
Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space
inferred← citeshttps://doi.org/10.1080/03639045.2024.2307421openalex-snapshot
Comparative pharmacokinetic evaluation of glimepiride orodispersable and conventional tablets in rabbits
inferred← citeshttps://doi.org/10.1080/15563650.2022.2112692openalex-snapshot
Glimepiride pharmacokinetics in overdose
inferred← citeshttps://doi.org/10.1080/17425255.2022.2132931openalex-snapshot
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes
inferred← citeshttps://doi.org/10.1093/jac/dkx036openalex-snapshot
No role for patient body weight on renal function assessment for drug dosing
inferred← citeshttps://doi.org/10.1097/ftd.0b013e3181eea55aopenalex-snapshot
A Review of Analytical Techniques for Determination of Glimepiride: Present and Perspectives
inferred← citeshttps://doi.org/10.1111/j.1463-1326.2011.01496.xopenalex-snapshot
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
inferred← citeshttps://doi.org/10.1111/j.1742-1241.2007.01362.xopenalex-snapshot
Pioglitazone plus glimepiride: a promising alternative in metabolic control
inferred← citeshttps://doi.org/10.14341/2072-0351-5525openalex-snapshot
Modern antihyperglycemic therapy: safety and efficacy of glimepiride
inferred← citeshttps://doi.org/10.1517/17425250903512955openalex-snapshot
The role of glimepiride in the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.2147/hiv.s33194openalex-snapshot
Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
inferred← citeshttps://doi.org/10.2147/vhrm.s33194openalex-snapshot
Glimepiride: evidence-based facts, trends, and observations
inferred← citeshttps://doi.org/10.21518/2079-701x-2022-16-23-199-204openalex-snapshot
Fixed combinations of hypoglycemic drugs in the treatment of patients with type 2 diabetes
inferred← citeshttps://doi.org/10.2165/11318100-000000000-00000openalex-snapshot
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
inferred← citeshttps://doi.org/10.2165/11599410-000000000-00000openalex-snapshot
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
inferred← citeshttps://doi.org/10.2298/vsp0612015jopenalex-snapshot
Bioequivalence assessment of the two brands of glimepiride tablets
inferred← citeshttps://doi.org/10.3389/fphar.2025.1686415openalex-snapshot
A digital twin of glimepiride for personalized and stratified diabetes treatment
inferred← citeshttps://doi.org/10.3390/ijms26041429openalex-snapshot
Combining Sulfonylureas with Anticancer Drugs: Evidence of Synergistic Efficacy with Doxorubicin In Vitro and In Vivo
inferred← citeshttps://doi.org/10.3390/ph18010122openalex-snapshot
The Clinical Pharmacokinetics and Pharmacodynamics of Glimepiride—A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.37987/1997-9894.2018.2(218).196122openalex-snapshot
Efficient and safe control of glycemia with the use of Gliclazide MR and Gliperamide in the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.3923/pjn.2016.194.202openalex-snapshot
Glycemic Reaction of Glimepiride Combined with Popular Egyptian Antidiabetic Drinks of Fenugreek and Coffee in Diabetic Rats
inferred← citeshttps://doi.org/10.70675/e35d8a2dz844fz4cfdz8f64z0870e357ae1fopenalex-snapshot
Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.